Christopher R. Gibson

Author

Also Known As

C Gibson, C R Gibson, C. GIBSON, C. Gibson, C. R. Gibson, Chris Gibson, Christoper R. Gibson, Christopher Gibson, Christopher R. Gibson, Gerard Goggin

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

United States Military Academy Merck & Co., Inc., Rahway, NJ, USA (United States)GlaxoSmithKline (United States)Novartis (United States)Bristol-Myers Squibb (United States)

About

Christopher R. Gibson is an author at United States Military Academy specializing in medicine, pharmacology, and pharmacokinetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	819
2	Health Sciences	2	2	25
3	Education	1	1	21
4	Engineering	1	1	13
5	Natural Sciences	1	1	34

Christopher R. Gibson

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance Barbara J. Ring, Jenny Y. Chien, Kimberly K. Adkison, Journal of Pharmaceutical Sciences Pharmacokinetic ModelingMedicineDrug DiscoveryPrediction MethodsPhrma Cpcdc Initiative	2011	198
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach Patrick Poulin, Rhys D.O. Jones, Hannah M. Jones, Journal of Pharmaceutical Sciences Precision DosingPhysiologically Based PharmacokineticsPharmacokinetic ModelingHuman PharmacokineticsMedicine	2011	170
Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug–Drug Interaction Trial Design Marc L. Reitman, Xiaoyan Chu, Xiaoxin Cai, Clinical Pharmacology & Therapeutics	2010	156
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution Rhys D.O. Jones, Hannah M. Jones, Malcolm Rowland, Journal of Pharmaceutical Sciences Translational MedicinePharmacokinetic ModelingPart 2Prediction MethodsMedicine	2011	133
IgG2m4, an engineered antibody isotype with reduced Fc function Zhiqiang An, Gail Forrest, Renée Moore, mAbs	2009	97
Evaluation of Various Static and Dynamic Modeling Methods to Predict Clinical CYP3A Induction Using In Vitro CYP3A4 mRNA Induction Data Heidi J. Einolf, L Chen, Odette A. Fahmi, Clinical Pharmacology & Therapeutics	2013	90
Estrogen receptor agonists and estrogen attenuate TNF- -induced apoptosis in VSC4.1 motoneurons Arabinda Das, J. A. Smith, Christopher R. Gibson, Journal of Endocrinology	2010	67
Boron Neutron Capture Therapy of Brain Tumors: Biodistribution, Pharmacokinetics, and Radiation Dosimetry of Sodium Borocaptate in Patients with Gliomas Joseph H. Goodman, Weilian Yang, Rolf F. Barth, Neurosurgery	2000	64
PhRMA CPCDC Initiative on Predictive Models of Human Pharmacokinetics, Part 1: Goals, Properties of the Phrma Dataset, and Comparison with Literature Datasets Patrick Poulin, Hannah M. Jones, Rhys D.O. Jones, Journal of Pharmaceutical Sciences Part 1Pharmacokinetic ModelingPharmacologyPhrma Cpcdc InitiativePhrma Dataset	2011	60
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration–time profiles in human from in vivo preclinical data by using the Wajima approach Ragini Vuppugalla, Punit Marathe, Handan He, Journal of Pharmaceutical Sciences Precision DosingTherapeutic Drug MonitoringPharmacokinetic ModelingPreclinical Drug EvaluationMedicine	2011	59

Page 1